TRP
data caveat$10M12mo
Tissue Repair
Biotechnology · Dermatology
Licensed RGTA (ReGeneraTing Agent) technology for wound healing and tissue repair. CACIPLIQ20 product in Phase 3 for scars.
Data HealthTrials1 of 1 active · stale enrollment
Cash data from Dec 2025 4CFigures from ASX filings · not financial advice
[ VITALS ]
Cash on Hand
$8.2M
Dec 2025 4C
Runway
12moADEQUATE
Based on Dec 2025 4C
Market Cap
$10M
Burn Rate
$2.1M/qtr
Dec 2025 4C
Shares Outstanding
60M
Pipeline Assets
2
Latest Insight(1)
27 Feb 2026Half YearAppendix 4D and Half Year Report to 31 December 2025
Cash$8.3M·Burn$4.0M/q·OCF$-4.0M
3M Price
TRP.ASX$0.170-50.0% 3M
Low $0.150High $0.340
Pipeline Assets (2)
CACIPLIQ20 (RGTA)Diabetic foot ulcers
Phase 2CACIPLIQ20 (RGTA)Post-surgical scars
Phase 3Discovery
Preclinical
Ph 1
Ph 1/2
Ph 2
Ph 2/3
Ph 3
NDA
Approved
CACIPLIQ20 (RGTA)
Capital Raises & Buybacks
show_chart
No capital raise or buyback data
Director Options & Rights
Director
Outstanding
Ex. Price
Expiry
No option data entered yet
Competitive Landscape
40 competitor trialsPhase 2+ · Non-ASX
Diabetic Foot Ulcers38 active trials
15 Ph46 Ph31 Ph2/39 Ph27 Ph1/PHASE2
Post-Surgical Scars2 active trials
1 Ph31 Ph2
Competitor trials from ClinicalTrials.gov (Phase 2+ historical, Phase 3+ refreshed weekly, active/recruiting, non-ASX sponsors). Approved drugs from OpenFDA (NDA/BLA only). Updated weekly via fetch_competitors.py.
expand_moreClinical Publications
Peer-reviewed papers & conference abstracts via PubMed
5 papers
Clinical Publications
Peer-reviewed papers & conference abstracts via PubMed
Carbohydr Polym2026-04· RGTA
Adv Healthc Mater2026-04
Catalysts (1)
TRIVIA Phase 3 interim analysis (100 patients)
UpcomingExpectedarrow_upwardHigh31 July 2026
| Event | Type | Confidence | Impact | Date | Status |
|---|---|---|---|---|---|
| TRIVIA Phase 3 interim analysis (100 patients) Binary go/no-go at 100 patients. Currently ~40 enrolled. Determines whether Phase 3 program continues | data readout | Expected | arrow_upwardHigh | 31 July 2026 | Upcoming |
Delivery Consistency Index
Historical delivery and spending consistency — data is limited for recently added companies.
Track record will build as data accumulates — we need completed catalysts with original guidance dates, or at least two quarterly 4Cs, before scoring kicks in.
Clinical Trials(6)
1 activeClinicalTrials.gov ↗
Ph2Not Yet RecruitingEnrollment stale · 445d
OTR4132Placebo
A Trial to Assess the Efficacy and Safety of OTR4132-MD in Patients with Acute Ischemic Stroke
Endovascular Thrombectomy · Ischemic Cerebrovascular Accident
RandomizedQuadruple Blind18 Years – 85 Years
Primary endpoint Baseline-Adjusted 24-Hour NIHSS
Announcements(7)
description
Half YearPSauto_awesome
Appendix 4D and Half Year Report to 31 December 202527 Feb 2026
expand_more934KB